TF
BMY.RT

Tompkins Financial’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Tompkins Financial’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-466
Closed – – 571
2020
Q4 		$0 Sell
466
-16
-3% -$34 ﹤0.01% 574
2020
Q3 		$1K Hold
482
– – ﹤0.01% 381
2020
Q2 		$2K Hold
482
– – ﹤0.01% 366
2020
Q1 		$2K Sell
482
-61
-11% -$201 ﹤0.01% 393
2019
Q4 		$2K Buy
+543
New +$1.41K ﹤0.01% 392

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Tompkins Financial's BMY.RT Position: Q1 2021 in Review

Tompkins Financial sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 466 shares.

Tompkins Financial first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Tompkins Financial reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Tompkins Financial sold 466 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Tompkins Financial first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Tompkins Financial's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Tompkins Financial's 13F filing for Q1 2021, filed 9 Jun 2021.